PH vs SGMO · P/E 28, rev $19.85B vs rev $57.8M
Parker-Hannifin Corporation (PH) versus Sangamo Therapeutics Inc (SGMO) — a side-by-side from cached financials, not a winner call.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Sangamo Therapeutics Inc (SGMO) is a biotechnology company listed on NASDAQ.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Latest reported SGMO revenue for 2024-12-31 was $57.8M. Net income was -$97.9M. Revenue was down 67.2% from 2023-12-31 to 2024-12-31. SGMO currently screens at market cap $74.6M.
PH currently screens at market cap $91.89B and trailing P/E 27.7. SGMO currently screens at market cap $74.6M.
Not investment advice. Open the PH and SGMO stock pages for the full models.
Not investment advice.